STOCK TITAN

Aeglea BioTherapeutics Inc - agle STOCK NEWS

Welcome to our dedicated news page for Aeglea BioTherapeutics (Ticker: agle), a resource for investors and traders seeking the latest updates and insights on Aeglea BioTherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aeglea BioTherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aeglea BioTherapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.23%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.23%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.22%
Tags
offering
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.22%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
conferences
Aeglea BioTherapeutics Inc

Nasdaq:AGLE

AGLE Rankings

AGLE Stock Data

48.63M
1.92M
3.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Austin

About AGLE

aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f